Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Berkshire Partners and Court Square Capital Partners have made a strategic investment in Thrive, a Massachusetts-based provider of cybersecurity and ...

Moniepoint has secured an investment from Visa (V), a global leader in digital payments. The investment marks an important milestone in Visa’s ...

A $20 million Lilly Endowment grant aims to make Gary and ... The funding will launch NWI Thrive, a multi-faceted project that will include new trails, trail improvements, educational campaigns ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

City rental studios thrive on demand for outfits such as long-trail dresses and tuxedos used in pre-wedding & maternity shoots Stay in style: Kolkata warms up to luxury outfit rentals Many in the ...

Arianna Huffington's Thrive Global has a new partnership with Eli Lilly, sharing tips for healthy living where patients already fill their prescriptions.

Last year, Thrive Global teamed up with OpenAI to create Thrive AI Health, an AI-powered health coach trained on the company’s behavior-change research and customers’ self-reported health data to ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...